PULIKE(SH:603566)2022-04-28 16:00Financial Performance - The company's operating revenue for Q1 2022 was approximately ¥245.29 million, representing a decrease of 20.54% compared to the same period last year[5]. - The net profit attributable to shareholders was approximately ¥37.52 million, down 56.80% year-over-year[5]. - The net profit after deducting non-recurring gains and losses was approximately ¥34.83 million, a decrease of 59.22% compared to the previous year[5]. - The total comprehensive income for the first quarter of 2022 was CNY 37,523,007.05, down from CNY 86,849,170.37 in the first quarter of 2021, indicating a decrease of about 56.9%[32]. - The basic and diluted earnings per share for the first quarter of 2022 were both CNY 0.12, compared to CNY 0.28 in the first quarter of 2021, reflecting a decline of approximately 57.1%[32]. Cash Flow and Liquidity - The net cash flow from operating activities was negative at approximately -¥8.50 million, an increase of 41.64% in outflow compared to the previous year[5]. - The net cash flow from operating activities for the first quarter of 2022 was negative CNY 8,500,573.99, an improvement from negative CNY 14,564,672.22 in the same period of 2021[37]. - Cash inflows from operating activities totaled CNY 204,732,960.36 in the first quarter of 2022, compared to CNY 233,335,334.97 in the first quarter of 2021, showing a decrease of about 12.3%[34]. - Cash outflows from operating activities amounted to CNY 213,233,534.35 in the first quarter of 2022, down from CNY 247,900,007.19 in the same period of 2021, indicating a decrease of approximately 14%[37]. - The net cash flow from investing activities was CNY 50,691,468.78 in the first quarter of 2022, compared to negative CNY 52,913,502.84 in the first quarter of 2021, showing a significant improvement[37]. - The cash and cash equivalents at the end of the first quarter of 2022 were CNY 243,614,922.68, an increase from CNY 172,778,796.83 at the end of the first quarter of 2021[37]. - The company received CNY 37,000,000.00 from borrowings in the first quarter of 2022, indicating active financing activities[37]. Assets and Liabilities - The total assets at the end of the reporting period were approximately ¥2.24 billion, an increase of 3.49% from the end of the previous year[7]. - Total assets reached CNY 2,243,983,991.38 as of March 31, 2022, compared to CNY 2,168,280,813.81 at the end of 2021, marking an increase of 3.5%[25]. - Total liabilities amounted to CNY 406,008,867.68 as of March 31, 2022, up from CNY 367,828,697.16 at the end of 2021, representing an increase of 10.3%[25]. - The company's retained earnings as of March 31, 2022, were CNY 1,017,448,491.22, an increase from CNY 979,925,484.17 at the end of 2021, showing a growth of 3.8%[25]. Revenue Breakdown - Revenue from pig vaccines decreased by 24.27% to approximately ¥83.49 million compared to the same period last year[8]. - Revenue from poultry vaccines and antibodies decreased by 10.85% to approximately ¥81.55 million year-over-year[8]. - Total operating revenue for Q1 2022 was CNY 245,291,876.69, a decrease of 20.5% compared to CNY 308,684,677.37 in Q1 2021[27]. - Total operating costs for Q1 2022 were CNY 199,560,937.12, down from CNY 205,374,036.34 in Q1 2021, reflecting a reduction of 2.0%[27]. - Research and development expenses for Q1 2022 amounted to CNY 15,802,688.91, a decrease of 20.5% from CNY 19,883,507.77 in Q1 2021[27]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 10,026, with the largest shareholder holding 33.47% of the shares[11].